Send us Feedback

Retrospettiva (BER:RSV)
Analysis
SUMMARY
BULLS
BEARS
QUOTE AND NEWS
NOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate
Globe Newswire  Oct 3  Comment 
- Well-tolerated with no systemic side-effect trends - Highly immunogenic with an increase in anti-RSV antibodies in 100% of subjects in the highest-dose group - Oral and poster presentations to be made at 5th Vaccine and ISV Annual Global
Novavax (NVAX) to Present Top-Line Data from RSV Vaccine Phase I
StreetInsider.com  Sep 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%29+to+Present+Top-Line+Data+from+RSV+Vaccine+Phase+I/6809882.html for the full story.
Soured motavizumab deal triggers MedImmune suit against partner Abbott
FierceBiotech  Aug 23  Comment 
Eight months after AstraZeneca ($AZN) wrote off a star program for motavizumab, along with $445 million, its MedImmune subsidiary in Maryland has fired off a nasty lawsuit against Abbott over their soured development pact for the RSV...
Scruble Cube Is Scrabble With A Twist
Forbes  Jul 7  Comment 
VideoScruble Cube combines two classic toys, Hasbro's Scrabble and Mattel's Rubik's Cube. It's a 3D word puzzle that's fun for solo play and a good portable family game. The maker boasts you can twist the cube into 7,401 septillion configurations,...
(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab
Stock Blog Hub  Dec 22  Comment 
AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US...
Day Trader's Alert: QDEL, ALNY, GMCR
Stock Wizard  Sep 29  Comment 
Shares of Quidel Corporation (NASDAQ: QDEL), jumped more than 6% after it announced that it has received 510(k) clearance from the United States Food and Drug Administration for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for...
Swings and Roundabouts at Biota – LANI and RSV
Fusion Investing and Analysis  Aug 10  Comment 
Biota released the following two significant announcements today, LANI is a success and RSV a dud. The market continue to digest the news in volatile fashion. Initial infatuation is currently giving way to fear of rejection. Putting this in...




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 


References

Retrieved from "http://www.wikinvest.com/stock/Retrospettiva_(BER:RSV)"
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki